10-Q/A: Renovaro Restates Q3 2024 Financials Due to Warrant and License Agreement Errors

Renovaro Inc. restated its Q3 2024 financial statements due to material misstatements related to warrant exercises and an impairment charge, impacting previously reported assets, losses, and earnings per share.

Summary

• Renovaro Inc. is filing an amendment to its Q3 2024 Form 10-Q/A to restate its financial statements as of and for the period ended March 31, 2024.
• The restatement was prompted by a material misstatement related to certain warrants exercised during the three months ended March 31, 2024, which were not appropriately reflected in the change in fair value of contingent consideration.
• An error in the method used to measure the impairment charge associated with the termination of a license agreement with Weird Science, LLC also contributed to the restatement.
• The company's management re-evaluated the effectiveness of the company's internal control over financial reporting (ICFR) as of March 31, 2024 and believes the error relates to and is the result of a previously identified and reported material weakness which has been disclosed in our Form 10-K filed on October 2, 2023.
• The restatement resulted in an overstatement of assets and an understatement of net loss and net loss per share for the three and nine months ended March 31, 2024.
• As of May 10, 2024, the number of shares of the registrant's Common Stock outstanding was 147,504,944.
• The company incurred a net loss of $58,990,070 and $72,694,219 for the three and nine months ended March 31, 2024, respectively.
• As of March 31, 2024, the company had cash and cash equivalents of $312,697 and an accumulated deficit of $316,723,472 and a working capital deficit of $19,654,098.

Sentiment

Score: 3

Explanation: The document indicates a negative sentiment due to the restatement of financial statements, material weaknesses in internal controls, substantial losses, and dependence on additional financing. While there are some positive aspects, the overall tone is concerning from an investment perspective.

Positives

• The company is streamlining its organization to focus on oncology and HIV therapies and its AI-driven cancer diagnostics platform.
• The company intends to secure additional funding through equity or debt financing.

Negatives

• The company's internal control over financial reporting was not effective as of March 31, 2024.
• The company has incurred substantial recurring losses from continuing operations.
• The company is dependent on additional financing to fund operations.
• The company has a working capital deficit of $19,654,098 as of March 31, 2024.
• The company recorded an impairment loss of $42,611,000 related to the termination of the license agreement with Weird Science LLC.

Risks

• The company's ability to continue as a going concern is in substantial doubt.
• The company may be unable to obtain additional funding on reasonable terms or at all.
• Failure to obtain required funding could lead to a material reduction or suspension of operations.
• The company is involved in several legal proceedings, which could have an adverse outcome.
• The company's disclosure controls and procedures were not effective as of March 31, 2024.
• The company may be unable to compete effectively in the intensely competitive biotechnology industry.
• The company's products may not perform as expected, which could materially and adversely affect the company's business, financial condition, results of operations and growth prospects.

Future Outlook

The company plans to focus on oncology and HIV therapies and its AI-driven cancer diagnostics platform, and intends to secure additional funding through equity or debt financing to support its operations and development activities.

Management Comments

• Management has reduced overhead and administrative costs by streamlining the organization to focus around two of its therapies (oncology and a HIV therapeutic vaccine) and investment in the development and validation of its AI driven cancer diagnostics platform.
• The Company has tailored its workforce to focus on these therapies.

Industry Context

The company operates in the competitive biotechnology and artificial intelligence-driven healthcare technology industries, requiring continuous innovation and adaptation to market changes.

Comparison to Industry Standards

• The company's competitors include Grail, Inc., Exact Sciences Corporation, Freenome, Inc. and Thrive Earlier Detection Corp., which have greater financial, technical and other resources.
• The company's success depends on its ability to demonstrate compelling advantages in the performance and convenience of its products, including on a cost-competitive basis.
• The company's success depends on its ability to achieve adequate coverage or reimbursement by third-party payors for its products.

Legal Proceedings

• The company is involved in securities class action litigation, federal derivative litigation, and state derivative litigation.
• The company filed a complaint against Serhat Gmrkc, William Anderson Wittekind, G Tech Bio LLC, SG & AW Holdings, LLC, and Seraph Research Institute.
• The company is defending against a complaint filed by its former Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc.
• The company is defending against a complaint filed by Weird Science LLC, Wittekind, and related trusts.
• Weird Science and Wittekind filed a shareholder derivative action in the United States District Court for the Central District of California against certain officers, directors, and investors of the Company, as well as other defendants.

Related Party Transactions

• As of March 31, 2024, the Company has accrued $ 111,750 of compensation related expenses for the Company's Chief Executive Officer, Mark Dybul, related to budget constraints.
• On March 26, 2024, the Company issued a Promissory Note to Paseco ApS, a Danish entity and greater than 5% shareholder, in the principal amount of $ 160,000.
• On February 5, 2024, the Company entered into an agreement with RS Bio to issue a 5 % Original Issue Discount Secured Promissory Note for the principal amount of $ 105,263.
• On January 2, 2024, the Company entered into an agreement with RS Bio to issue a 5 % Original Issue Discount Secured Promissory Note for the principal amount of $ 526,315.
• On November 3, 2023, the Company entered into an agreement with RS Bio to issue a 5 % Original Issue Discount Promissory Note for the principal amount of $ 1,000,000.
• On October 10, 2023, the Board of Directors of the Company (the Board) appointed Avram Miller to the Board, effective October 11, 2023, to fill a vacancy.
• On August 1, 2023, RS Bio, purchased in a Private Placement 70,126 of the Company's Units at a price per Unit equal to $7.13 for aggregate proceeds to the Company of $500,000.
• On August 1, 2023, Paseco ApS, in connection with the Private Placement, converted $2,000,000 of its Promissory Note into 280,505 of the Company's Units at a price per Unit equal to $7.13.
• The Company currently has a consulting agreement with Paseco ApS for business advisory services since December of 2019.

Stakeholder Impact

• Shareholders face potential dilution from future equity financing.
• Employees may be affected by cost-cutting measures and organizational restructuring.
• Customers may experience delays or disruptions in service due to the company's financial challenges.
• Suppliers and creditors face increased risk of non-payment due to the company's financial instability.

Next Steps

• The company plans to complete IND-enabling activities for RENB-DC11 in the second half of 2024, with potential clinical trials in humans during the first half of 2025.
• The company intends to secure additional funding through equity or debt financing.
• The company will continue to defend against legal proceedings.

Key Dates

Keywords

restatement, financial statements, warrants, impairment, internal control, going concern, Renovaro, RENB, financials